Fulcrum Therapeutics (FULC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, to be held virtually for stockholders of record as of April 27, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class I directors for three-year terms expiring at the 2029 annual meeting: Sonja Banks, Alan Ezekowitz, and Colin Hill.
Non-binding advisory vote on executive compensation (say-on-pay).
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Provision for transaction of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals on the agenda.
Latest events from Fulcrum Therapeutics
- Discontinued lead program, restructured operations, and reviewing strategic alternatives amid ongoing losses.FULC
Q2 2026 - Pociredir Phase 1b readouts in sickle cell disease expected in 2025, with pipeline expansion underway.FULC
Leerink’s Global Healthcare Conference 2025 - Director elections, executive pay, and auditor ratification headline the 2026 annual meeting.FULC
Proxy filing - Pociredir demonstrated strong efficacy and safety in SCD, supporting advancement to late-stage trials.FULC
Corporate presentation - Pociredir showed strong efficacy and safety, with $333M cash runway supporting operations into 2029.FULC
Q1 2026 - Pociredir achieved rapid, robust HbF increases and improved outcomes in sickle cell disease.FULC
44th Annual J.P. Morgan Healthcare Conference - Pivotal study planned after strong PIONEER data, with focus on sickle cell and U.S. launch.FULC
Leerink Global Healthcare Conference 2026 - Pociredir achieved strong HbF induction and safety in SCD, advancing toward pivotal trials.FULC
Corporate presentation - Strong HbF induction, clinical benefit, and cash runway support pivotal trial in 2026.FULC
Q4 2025